Comments
Loading...
Accelerate Diagnostics Stock Guidance | NASDAQ:AXDX | Benzinga
Accelerate Diagnostics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 01/07/2024 | AXDX | Accelerate Diagnostics | FY | 2023 | — | — | — | $12.10M | $12.10M | $12.81M | Get Alert |
| 01/13/2022 | AXDX | Accelerate Diagnostics | Q4 | 2021 | — | — | — | $3.30M | $3.30M | $3.92M | Get Alert |
| 01/13/2022 | AXDX | Accelerate Diagnostics | FY | 2021 | — | — | — | $11.80M | $11.80M | $12.28M | Get Alert |
| 01/12/2021 | AXDX | Accelerate Diagnostics | Q4 | 2020 | — | — | — | $3.10M | $3.10M | $4.41M | Get Alert |
| 01/12/2021 | AXDX | Accelerate Diagnostics | FY | 2020 | — | — | — | $11.20M | $11.20M | $12.43M | Get Alert |
FAQ
What is the most recent guidance for Accelerate Diagnostics (AXDX)?
There have been no specific sales or earnings guidance reported for Accelerate Diagnostics in recent months.
Browse guidance and forecast on all stocks.